Q-omics provides the consensus-scored RPL23AP83 profile across patient tissues and cancer cell-line models. RPL23AP83 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RPL23AP83 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, RPL23AP83 RNA expression shows 6,526 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UCEC, BLCA, and KIRC as cancer lineages where RPL23AP83 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP83 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP83 survival associations across molecular data types. RPL23AP83 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP83 RNA expression–survival associations across cancer types. High RPL23AP83 expression shows unfavorable associations in UCEC, LIHC, ACC and MESO, but favorable associations in CESC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for RPL23AP83 RNA expression.
This table summarizes RPL23AP83 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP83. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP83 shows lower tumor expression in PAAD and THCA and higher tumor expression in BLCA, KIRP, LUSC and KIRC. The BLCA box plot shows higher RPL23AP83 RNA expression in tumor versus normal tissue (log2 FC = +0.194, t-test p = .002).
This table shows molecular features associated with RPL23AP83 in patient tissues and cancer cell lines. In patient samples, RPL23AP83 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
